January 10, 2022 – January 13, 2022

KPMG at the 40th Annual J.P. Morgan Healthcare Conference 2022


Kristin C. Pothier

Kristin C. Pothier

Global & National, HCLS Deal Advisory & Strategy Leader, KPMG US

+1 617 549 2779

Janet Lehman

Janet Lehman

Partner, Audit, U.S. Venture Capital Life Sciences Leader, KPMG US

Brett Glover

Brett Glover

National Financial Due Diligence and Deal Advisory Strategy Leader, Healthcare and Life Sciences, KPMG US

+1 214-840-8579

Jeff Stoll, PhD

Jeff Stoll, PhD

Principal, National Strategy Life Sciences Leader, KPMG US

+1 857-334-8768

This year KPMG will be hosting a series of events to coincide with the 40th Annual J.P. Morgan Healthcare Conference. Hear from leading industry luminaries, emerging fast-growth companies, innovative technology creators, and members of the investment community and get forward-thinking perspectives and insights on key life sciences and healthcare topics.

We welcome you to join us for the following events:

  • January 12-13, 2022
  • January 17, 2022

January 12-13, 2022

January 12-13, 2022 | Goodwin + KPMG @JPMorgan Symposium

This virtual two-day Symposium is devoted to accelerated innovation in the healthcare and life sciences industry. Held during the 40th Annual J.P. Morgan Healthcare Conference week, you will hear from our top strategy, legal, and financial partners as they engage luminaries across the life sciences and healthcare industries around the future of innovation and dealmaking worldwide.

This is a two-day learning experience that will explore key themes in healthcare and life sciences, including:

  • Healthcare transformation, disruption, and innovation
  • Exploring the European biotech landscape
  • Capital market insights: The state of the market and how to access the public market 
  • Keys to unlocking innovative strategies in dealmaking

Register for Day One: Wednesday, January 12

Register for Day Two: Thursday, January 13    


Goodwin + KPMG @ JPMorgan Symposium
Full Agenda (all times Eastern)


10:30 – 10:40 am

Welcome Remarks

10:40 – 10:50 am

Ignite Talk | The State of the European Biotech

  • David Mardle, Partner, Goodwin
  • Anne-Charlotte Rivière, Partner, Goodwin
10:50 – 11:20 am

Panel | Evolving European Biotech Landscape

This panel will address the challenges and dynamics of various clusters of biotech innovation in Europe with the UK being the leader as well as other strong centers such as Nordics. We will also discuss emerging clusters that are a couple of years behind the UK and Nordics but are the next places to be such as France and Germany and other continental parts of Europe.

  • Sophie McGrath, Partner, Goodwin (Moderator)
  • Jasper Bos, Ph.D., General Partner, Forbion
  • Rachel Mears, Partner, Jeito Capital
  • Soren Moller, Managing Partner, Novo Holdings 
11:20 – 11:50 am Fireside Chat | Topic TBD
11:50 am – 12:00 pm Break
12:00 – 12:10 pm

Ignite Talk: Hot Topics in 2022 and Beyond in the Healthcare Regulatory Environment

  • Matt Wetzel, Partner, Goodwin
12:10 – 12:40 pm

Panel | An Industry in Transformation 

In recent years, we have seen several technology companies attempt to transform their businesses by adding healthcare components and developing products and apps that are regulated by the FDA. Conversely, we have also seen traditional medical technology companies develop products that enable data platforms that hold vast amounts of aggregated patient and prescriber data. As tech companies trend towards healthcare, and as healthcare companies move towards tech, this panel will explore what challenges these companies face in terms of competition, regulatory controls and government oversight.

12:40 – 1:10 pm

Fireside Chat | Innovation in Women’s Health and Wellbeing: Critical Legal Considerations

We are at a turning point in the transformation of healthcare, and technological innovation in the Women’s Health and Wellbeing sector has never been stronger. The industry is expected to reach $41 billion by 2027 and is experiencing a newfound interest in removing the barriers that stalled its growth for decades. The evolution of the industry raises important legal issues and regulatory challenges that must be overcome to propel the industry forward. This fireside chat will address why the sector is attracting more investment, the legal structures that must be shifted to facilitate this evolution, the role that technology is playing in transforming the space, and where technological innovation still needs to catch up to improve the lives of women everywhere. 

  • Delphine O’Rourke, Partner, Goodwin (Moderator)
  • Sandy Milligan, M.D., J.D., Head of Research and Development, Organon
1:10 – 1:40 pm

Panel | Privacy Guardrails for the Digital Healthcare Revolution

Large-scale digital processing of sensitive personal data has powered technology that has brought treatment and support to countless patients.  From access to mental health, nutrition guidance and medicine to patient portals and support communities, and to medical research, entrepreneurs have created technology to improve and save lives. This panel will look at the data trends and technologies that are reshaping healthcare, and how companies can handle sensitive personal data fairly and transparently, respecting privacy and data protection laws and societal expectations, as well as articulate their privacy-protective stance to patients, regulators and the society at large. Our discussion will touch on the evolving global privacy landscape, including in the United States, Europe and other parts of the world, and offer participants practical guidance on privacy compliance guardrails in health tech. 

  • Boris Segalis, Partner, Goodwin (Moderator)
  • Lore Leitner, Partner, Goodwin
  • Gordon Kessler, CAO General Counsel, AiCure
1:45 – 2:30 pm

Keynote | Fireside Chat with Cerevel Therapeutics CEO, Tony Coles

  • Stuart Cable, Partner, Goodwin (Moderator)
  • Tony Coles, M.D., CEO and Chairperson, Cerevel Therapeutics


1:00 – 1:15 pm

Ignite Talk | State of the Capital Markets

  • Jack Bannister, Managing Director – Equity Capital Markets, SVB Leerink 
1:15 – 1:55 pm

Panel | Accessing the Public Markets: Chart Your Own Course. 

This interactive life sciences capital markets panel will focus on the key steps for deciding which type of offering to pursue, best practices for preparing and executing a capital markets transaction, ways to mitigate litigation risk along the way, and what you can expect to encounter as a newly public company.

1:55 – 2:00 pm Break
2:00 – 2:30 pm

Fireside Chat | Stories From the Front

2:40 – 3:25 pm

Fireside Chat |  A Fly in the Ointment? Antitrust Expansion in Life Sciences Collaborations and Combinations

The Federal Trade Commission (FTC) and other competition agencies across the globe have increased their scrutiny of transactions in the life sciences industry. The FTC has spearheaded the formation of a Multilateral Pharmaceutical Merger Task Force to explore potentially new theories of harm and new ways to analyze the competitive effects of proposed transactions. At the same time, the industry continues to be innovative in its deal making to manage the technical, regulatory and commercial risks. This fireside chat will address the unique antitrust issues that arise when smaller innovative life sciences companies collaborate with or get acquired by big pharma, and how the new trends in antitrust scrutiny might affect such transactions. 

  • Lisa Haddad, Partner, Goodwin (Moderator)
  • Arman Oruc, Partner, Goodwin
  • Andy Lacey, Partner, Goodwin
3:25 – 3:30 pm Break
3:30 – 4:10 pm

Fireside Chat | Approaching a New 2022: The Real Keys to Innovative Deal Making This Year

Over the last year, despite the ongoing challenges of the pandemic, the life sciences industry has seen some of its most innovative deals to date. This panel will highlight lessons learned from these deals, including the need to get creative, and discuss which tactics are here to stay.

January 17, 2022

January 17, 2022 | HCLS Outlook Report release

Hear from KPMG Healthcare & Life Sciences Deal Advisory & Strategy leaders as they provide an in-depth discussion of our newly released 2022 Healthcare and Life Sciences Outlook Report.

Additional details to come. Check back here for more information.